Sanofi announces a savings plan of 2 billion euros and the cessation of its Consumer Health activity

Sanofi wants to focus on its core business: the research and development of innovative treatments and vaccines for patients. To do this, the company wants to separate itself from the activity dedicated to non-prescription drugs such as Doliprane, by listing it on the stock market.

This concerns their two production sites in France, in Lisieux (Calvados) and Compiègne (Oise), or 1,600 jobs. This reorganization will not take place before the fourth quarter of 2024, after consultation with the social partners. At the same time, the group is targeting savings of two billion euros by 2025, and ensures that the majority will be reallocated “financing innovation and driving growth”.

The project provokes the anger of Jean-Louis Peyren, coordinator of the CGT Sanofi: “It’s yet another savings plan. Workforce which will decrease further. You should know that Sanofi, between 2008 and 2023, we went from 27,500 employees on permanent contracts in France to just under 19,900”. The unions and management had a first meeting on Friday October 27 to discuss these projects.